FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 12:27:47 26/06/2024 am IST | ||
| 0.47 EUR | +2.17% |
|
| Current month | -40.51% | ||
| 1 month | -42.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 0.47 | +2.17% |
| 24/24/24 | 0.46 | -9.80% |
| 21/24/21 | 0.51 | +2.00% |
| 20/24/20 | 0.5 | -9.09% |
| 19/24/19 | 0.55 | +3.77% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 12:27 am IST
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2LTW |
| ISIN | DE000JK2LTW3 |
| Date issued | 23/02/2024 |
| Strike | 527.7 $ |
| Maturity | Unlimited |
| Parity | 114.59 : 1 |
| Emission price | 2.53 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.23 € |
|---|---|
| Lowest since issue | 0.39 € |
| Spread | 0.04 € |
| Spread % | 7.84% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
